GLP-1 Receptor Biology and the Therapeutic Role of Incretin-Based Agonists in Metabolic Diseases.
Type 2 diabetes (T2DM) and obesity represent a growing global health burden, sharing underlying pathophysiological mechanisms such as impaired insulin signalling and chronic low-grade inflammation. The discovery of the incretin effect opened the way for agonist therapies targeting the glucagon-like peptide-1 receptor (...